News

Eli Lilly Stock (LLY) is Stronger as it Fights for Alzheimer’s Drug Approval in Europe
Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...
Trade Tracker: Bill Baruch buys Eli Lilly, McDonald's, and Palantir
Bill Baruch, founder & president at Blue Line Capital, joins CNBC’s 'Halftime Report' to detail his latest portfolio moves.
Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...
This veteran investor is known for spotting winning stocks. Here’s why he’s all-in on Nvidia and Eli Lilly.
Stock-market veteran Louis Navellier, the chairman and founder of investment firm Navellier & Associates, is well-known for ...
Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...
Lilly requests EMA to re-examine Alzheimer's drug recommendation
Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency ...
Fierce Pharma2d
Texas outsourcer in Lilly's compounded tirzepatide lawsuit hit with FDA warning letter
A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year. | The FDA has ...